To evaluate the use of a pharmacogenetic and pharmacoepigenetic panel for predicting chemotherapy- and immunotherapy-induced cardiotoxicity in cancer patients.
Patients with a confirmed diagnosis of breast cancer who are scheduled to initiate treatment with anthracyclines and/or HER2-targeted therapies (anti-HER2 therapies).
Patients with a left ventricular ejection fraction (LVEF) < 50%;
Patients who have undergone chemotherapy and/or radiotherapy within the previous year;
Patients with chronic kidney disease and a glomerular filtration rate (GFR) < 30 mL/min/1.73 m²;
Patients with uncontrolled hypertension;
A prospective cohort of adult breast cancer patients receiving cardiotoxic cancer therapies, followed for cardiovascular assessment and multi-omics profiling to identify predictors of treatment-related cardiotoxicity.
Cohort
Prospective
Not listed
Cardiotoxicity
Throughout treatment and follow-up, cardiotoxicity will be defined according to the criteria established by the 2022 European Society of Cardiology (ESC) Cardio-Oncology Guidelines.
Click on the lead sponsor to view all of their trials.
